Top Health Tech Companies With Best Stability & Growth (10,000+)

Strong Revenue Growth: Revenue is reported as expanding rapidly, with more than 60% year-over-year growth in committed ARR in 2024. External recognitions like Deloitte Technology Fast 500 and repeat Inc. 5000 placements point to sustained multi-year momentum.

Market Expansion: New health plan partnerships and an increase to 17 health plans by 2026, alongside 12 million annual prior authorizations and 25M covered lives, indicate a widening commercial footprint. Integrations such as Epic’s Payer Platform and expanded relationships with national and regional plans reinforce adoption.

Investor Backing & Capital Strength: A $90 million Series C in 2025 brought total funding to roughly $200 million. Successive raises and participation from prominent investors suggest ample capital to support scaling.

Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.

Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.

Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.

Profitability: Company materials describe sustained annual profitability since 2023 and cash-flow positivity, pairing growth with disciplined financial health. It also reports meeting efficiency benchmarks, noting it exceeded the Rule of 40 in 2025.

Strong Revenue Growth: Disclosures point to multi-year revenue expansion with momentum described as accelerating, indicating robust top-line performance. This growth is presented alongside expanding provider and patient scale.

Strategic Partnerships: The platform is increasingly embedded across external channels through integrations with Healthgrades, Yelp, Google Gemini, and payer portals, broadening distribution and demand capture. These arrangements signal deeper ecosystem reach beyond the core marketplace.

Strong Revenue Growth: Inc. 5000 recognitions cite 82% and 72% three-year growth, and investor disclosures note meaningful 2025 revenue scale, indicating sustained multi-year expansion. While precise YoY rates aren’t public, repeated list appearances and disclosed scale point to continued momentum.

Investor Backing & Capital Strength: Nordic Capital became the majority owner in 2025 to support the next phase of growth, expansion, and platform investment. Additional financing and stated plans for strategic acquisitions further reinforce access to growth capital.

Market Expansion: Customer and data footprint expanded to 170M+ patient records across 200+ provider/payer organizations, with more than 2.25M value-based lives added in 2024. Management and media describe ambitions for further expansion via M&A and potential moves beyond the U.S.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Investor Backing & Capital Strength: Evidence indicates a $55M Series B in 2026 brought cumulative funding above $73M to accelerate hiring, R&D, and platform adoption. This capital position supports scaling operations and product development.

Strong Revenue Growth: Company materials state revenue increased 4× in the 12 months prior to April 2024, with earlier periods citing 24× growth and expectations to more than double in 2022. These signals indicate rapid top-line expansion, though current figures are not independently audited.

Product Line Growth: The offering has expanded beyond payment integrity into utilization management and appeals while launching AI agents for DRG validation, readmissions, and emergency-department reviews. This broadening scope increases relevance across health‑plan claims workflows.

Strong Revenue Growth: Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.

Strategic Partnerships: Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.

Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.

Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.

Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Strong Revenue Growth: Revenue is reported to have surpassed the $100 million annual mark with continued year-over-year gains. Feedback suggests momentum is reinforced by growth in newer verticals such as education and hospitality.

Market Expansion: The company extended its footprint from North America into the UK and Ireland and broadened placements beyond offices into campuses, hotels, gyms, warehouses, and other venues, while scaling to more than 6,000 customers. Feedback suggests international entry and vertical diversification are driving a larger installed base and usage milestones such as surpassing one billion single-use containers avoided.

Product Line Growth: The offering advanced from smart water coolers to a connected beverage platform, adding functional enhancements and a better-for-you soda line alongside new countertop hardware. Feedback suggests the expanded menu increases relevance across more locations and upsell potential within existing accounts.

Market Expansion: Customer reach is expanding across large U.S. health systems, with cited growth from 14+ systems in 2022 to 20+ more recently and examples of system‑wide expansions (e.g., Northwell Health). This footprint is described as covering thousands of leaders and hundreds of thousands of frontline staff, indicating broader adoption.

Product Line Growth: The platform has added meaningful capabilities, including the 2025 launch of AI‑powered Performance Insights and modules spanning engagement, performance/development, overtime/attendance, and patient rounding/audits. This suggests a strategy to deepen value and expand use cases within existing customers.

Strong Revenue Growth: Historical revenue expansion is externally signaled by Laudio’s #95 placement on Deloitte’s 2023 Technology Fast 500. This recognition aligns with the broader picture of rapid past scaling.

Product Line Growth: The company expanded beyond clinical messaging into pre-hospital communication, transfers, scheduling, alarm management, nurse call, smart rooms, and patient engagement, supported by launches like Pre-Hospital, Transfer, CareConduit, and Alarm Management plus the Twiage and eVideon acquisitions. This breadth indicates a shift toward a comprehensive healthcare-orchestration platform.

Investor Backing & Capital Strength: Approximately $448.6 million has been raised across 10 funding rounds, including a $300 million investment from Vista Equity Partners in 2022. This capital base supports scaling in engineering, product, and go-to-market, exemplified by the Mexico City office expansion.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000, including the 2026 list, is presented as evidence of substantial multi-year revenue growth. This external marker aligns with usage expansion to more than 1 million care-team members across nearly 6,000 organizations.

Strong Revenue Growth: Recent results show steady top-line expansion: FY2025 rose 9.3% and FY2026 quarters continued to grow in the mid‑single digits, with full‑year guidance at 4%–6%. Management indicates both U.S. and International Healthcare Solutions are expected to expand, sustaining momentum.

Profitability: Adjusted operating income and EPS increased at double‑digit rates (e.g., FY2025 AOI +15.8% and EPS +16.3%, with Q3 FY2026 EPS +12%), and guidance points to 13%–14% adjusted operating income growth. Outlook also includes solid adjusted free cash flow of around $3.0B.

Strong Market Position & Advantage: The company is consistently portrayed as one of the three dominant U.S. pharmaceutical distributors, reflecting scale, reach, and entrenched relationships. This position supports durable volumes in specialty categories and international distribution.

Strong Market Position & Advantage: Adoption spans 1,300+ biotechnology organizations with usage reported across more than half of the top 50 biopharma companies, signaling durable positioning in life‑sciences R&D software. Multiple sources characterize the platform as a leading life‑sciences R&D cloud used by both startups and major enterprises.

Product Line Growth: The company continues to launch and expand major offerings, including Benchling AI, antibody‑discovery capabilities, automation/analysis tools, and extensions into new scientific workflows such as small‑molecule chemistry. Acquisitions like PipeBio further broaden capability depth in biologics and related R&D domains.

Innovation-Driven Growth: AI is a clear growth vector, with reports that 500 biotech companies used Benchling AI in its first year and the product subsequently reached general availability. Team acquisitions (e.g., ReSync Bio and Sphinx Bio) and partnerships (e.g., with Anthropic) underscore a deliberate push to embed advanced models into scientific workflows.

Strong Revenue Growth: Management stated consistent double‑digit expansion with revenue growing more than 40% in the prior year, alongside significant market‑share gains. Plans to double headcount and a move into a 3× larger office reinforce the current growth trajectory.

Product Line Growth: The platform has expanded from core EHR/eMAR into CRM, billing and payments, occupancy/revenue tools, BI, family engagement, and AI (Ask ALIS), and added AI‑enabled dementia/behavioral‑care capabilities via its first acquisition. This broader suite increases revenue opportunity per customer and signals scaling beyond a single‑product footprint.

Market Expansion: The company reports serving assisted living, memory care, independent living, and behavioral‑care communities in more than 40 states, with usage across 3,000+ communities and 200,000 residents. An active partner ecosystem and 130+ integrations also indicate widening reach.

Strong Revenue Growth: Revenue is reported to have expanded dramatically over a recent three-year period, earning recognition on a leading high-growth list. Feedback suggests this reflects substantial commercial traction rather than growth based solely on financing.

Strong Market Position & Advantage: Customer adoption spans 500+ MedTech companies, including deep penetration among the largest enterprises (e.g., 16 of the top 20). Feedback suggests this breadth and upmarket presence signal durable positioning within its niche.

Investor Backing & Capital Strength: Capital raised has surpassed $160M with a recent late-stage round and a valuation near the unicorn threshold. Feedback suggests this funding base supports continued product expansion, AI initiatives, and go-to-market scale.

Market Expansion: International footprint is described as rapidly scaling, with the oncology research network tripling year over year and later noted as nearly 70% ex‑U.S. growth across the UK, Germany, Japan, and new regions like Scotland. Point‑of‑care reach is also portrayed as expanding, with 1,600+ sites of care and increases from earlier baselines.

Product Line Growth: New offerings include the launch of Flatiron Telescope and multiple AI-enabled datasets, alongside expansions of major assets such as the NSCLC Panoramic dataset. Additional capabilities like LLM-based data extraction and new hematology datasets indicate broader, monetizable product breadth.

Strategic Partnerships: Collaborations are highlighted with organizations such as NCCN, Quest Diagnostics, Candid Health, TailorMed, and DeepScribe, as well as a multi‑year partnership alongside the Paradigm transaction. Engagements with 20+ global oncology drug developers and academic institutions reinforce a partnership‑driven operating model.

Market Expansion: Operations have expanded from 3 to 14 and then 20+ states, with 8,800+ patients served and 17,700+ completed service requests by April 2025. Ongoing recruitment of transportation partners across Georgia and South Carolina underscores continued footprint growth.

Product Line Growth: Offerings now span transportation, interpretation, prescription delivery, post-procedure care, home health, and telemedicine within an integrated coordination platform. This broadened scope indicates expansion beyond a pure NEMT broker into a wider patient-access solution.

Investor Backing & Capital Strength: External sources cite roughly mid–single-digit millions raised across multiple seed rounds, including an oversubscribed Seed-3 in early 2023. Participation in programs with institutions such as Morgan Stanley and Mastercard Start Path signals ongoing investor support.

Investor Backing & Capital Strength: Recent financings include a $55M Series B led by Insight Partners and a prior $15M Series A, bringing total reported funding to roughly $77M. These capital events coincide with visible signals like active hiring and continued platform build-out.

Strong Revenue Growth: Growth is repeatedly described as 5x year-over-year since the Series A, alongside a 5x increase in valuation. Customer adoption reportedly expanded to 250+ CPG brands with $30B+ in retail sales planning flowing through the platform.

Product Line Growth: The offering has broadened from cash application and deductions into trade promotion management, sales forecasting, demand/supply planning, and analytics. Additions such as AI contract reading, auto‑disputes, and the Muffin Data acquisition indicate ongoing capability expansion.

Strong Revenue Growth: Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.

Investor Backing & Capital Strength: Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.

Market Expansion: Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.